The mevalonate pathway in breast cancer biology

Publikation: Beitrag in FachzeitschriftÜbersichtsartikel (Review)BeigetragenBegutachtung



Breast cancer affects one in eight women during their lifetime. Although diagnostic and therapeutic options have improved, recurrence, metastasis, and therapeutic resistance remain clinical challenges, which affect life quality and prognosis. The mevalonate pathway is an essential part of cellular homeostasis by providing a number of essential isoprenoid products including cholesterol. However, the disturbance of this pathway paralleled by increased bioavailability of its products and their direct involvement in several steps of tumorigenesis has highlighted the mevalonate pathway as a promising hub in cancer treatment. In this review, we will specifically discuss how the mevalonate pathway affects breast cancer biology in terms of supporting and modulating soluble and cellular factors and distinct steps of tumorigenesis. We will further summarize antitumor effects of the mevalonate pathway-inhibiting drugs, statins and amino-bisphosphonates, in breast cancer and discuss how they are used for future precision therapy.


Seiten (von - bis)215761
FachzeitschriftCancer letters
PublikationsstatusVeröffentlicht - 28 Aug. 2022

Externe IDs

Scopus 85131410080
unpaywall 10.1016/j.canlet.2022.215761
WOS 000810179200005
Mendeley 7b50887c-fc7b-3e04-ac48-557f38d32d0e
ORCID /0000-0002-8691-8423/work/142236006


Forschungsprofillinien der TU Dresden

DFG-Fachsystematik nach Fachkollegium

Fächergruppen, Lehr- und Forschungsbereiche, Fachgebiete nach Destatis

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete


  • Biology, Breast Neoplasms/drug therapy, Cell Transformation, Neoplastic, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Mevalonic Acid/metabolism, Rho-GTPases, Amino-bisphosphonates, Breast cancer, Cholesterol, Statins